Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Novacyt S.a. LSE:NCYT London Ordinary Share FR0010397232 EUR1/15TH (CDI)
  Price Change % Change Share Price Shares Traded Last Trade
  -14.80 -3.48% 410.10 974,534 13:27:29
Bid Price Offer Price High Price Low Price Open Price
410.00 410.60 425.00 400.00 425.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 13.08 -3.91 -14.00 290
Last Trade Time Trade Type Trade Size Trade Price Currency
13:27:29 AT 830 410.10 GBX

Novacyt (NCYT) Latest News

More Novacyt News
Novacyt Investors    Novacyt Takeover Rumours

Novacyt (NCYT) Discussions and Chat

Novacyt Forums and Chat

Date Time Title Posts
15/4/202113:00COVID-1952,884
15/4/202108:18CV and The Deep State164
22/3/202112:34Coranavirus2,310
01/3/202105:10coronavirusTransmission facts vs fiction473
08/1/202110:31COVID-19..downgraded no longer high consequence infectious disease37

Add a New Thread

Novacyt (NCYT) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
12:21:37409.15243994.22O
12:17:18409.211,7207,038.41O
12:16:48408.445002,042.20O
12:16:00408.44126514.63O
12:12:53409.491,2265,020.35O
View all Novacyt trades in real-time

Novacyt (NCYT) Top Chat Posts

DateSubject
15/4/2021
09:20
Novacyt Daily Update: Novacyt S.a. is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker NCYT. The last closing price for Novacyt was 424.90p.
Novacyt S.a. has a 4 week average price of 391p and a 12 week average price of 391p.
The 1 year high share price is 1,260p while the 1 year low share price is currently 210p.
There are currently 70,626,248 shares in issue and the average daily traded volume is 3,563,527 shares. The market capitalisation of Novacyt S.a. is £290,273,879.28.
15/4/2021
12:39
bobdown2: News to move the share price.. up or down the obvious area to look is DHSC news. A successful conclusion could rapidly take the share price back to the 600 to 700 pence area.
11/4/2021
15:52
bobaxe1: All credit to Rovers over on Stocko :Novacyt Sa (LON:NCYT): The Novacyt Share Price is an interesting one and as Paul mentioned above, a tough one to value. The NHS contract provided a steady stream of income however the price paid by the NHS was much lower than any private market ask.The UK Government is keen to move testing away from a centralised NHS offering to a private market as outlined in this recently released publication - Private COVID-19 testing validation - https://t.co/lmAS9KT9uR (https://t.co/mylH3vpSTh).PCR vs LFTPCR testing is here to stay due to two main characteristics: Accuracy & Variants. As quicker tests commonly referred to as Lateral Flow Tests become more popular, these will allow us to return to some sort of normality - mass testing. However these tests have faced a considerable backlash over accuracy and concerns around efficacy against specific variants. In settings where variant screening and accuracy are of paramount importance, PCR will continue to dominate. This includes hospitals, travel and care homes to name but a few.Market TrendsNovacyt has placed a big bet on rapid PCR testing outside of the lab. Through the introduction of VersaLab, PROMate, Q-Machines, Rapid HT-PCR tests and VariPlex, Novacyt has produced a service that enables people to conduct a PCR test outside of a lab with results available in 60-90 minutes. This is quite simply an unrivalled user experience and means the company is well positioned to capitalise on a decentralised diagnostics market going forward. It is also important to remember that Novacyt have over 550 tests allowing individuals to test for far more than just COVID-19.Unfortunately I think the COVID-19 pandemic is very similar to the way the market views technology trends. People over estimate the initial power of technology and significantly underestimate the power in the long term. In my opinion this can be applied to the pandemic: People overestimate how quickly it will subside and underestimate the longevity. Unfortunately as a result, testing could be here to stay for a significant period of time especially as variants continue to mutate as the virus comes under increasing pressure.FinancialsBased on 2020 figures and not taking into account the current DHSC dispute, Novacyt produced £277 million in revenue and £187 million EBITDA (margin of c.68%). EBITDA is then converted into cash at an 80% rate.Using this ratio, revenue of £72 million in Q1 2021 gives an EBITDA of c.£48 million resulting in cash of c.£38 million. This would put Novacyt's cash position at an eye watering £130 million.With the current market cap of £330 million, Novacyt would be valued at c.X2.5 cash position which seems incredibly cheap given the recent hiring spree, world class R&D, continued revenue production and consistent demand for their services. Sentiment is at an all time low with this stock however peers in the industry continue to be valued on X10 revenue as seen by recent M&A activity.There are definite headwinds for the company to deal with and their PR strategy has resulted in a number of disgruntled shareholders, however very few companies in the world have a gold standard product, operate at 80% margins, are completely debt free and sit on c.£100 million cash.
11/4/2021
12:35
glasswala: All credit to Rovers over on Stocko :Novacyt Sa (LON:NCYT): The Novacyt Share Price is an interesting one and as Paul mentioned above, a tough one to value. The NHS contract provided a steady stream of income however the price paid by the NHS was much lower than any private market ask.The UK Government is keen to move testing away from a centralised NHS offering to a private market as outlined in this recently released publication - Private COVID-19 testing validation - GOV.UK (www.gov.uk).PCR vs LFTPCR testing is here to stay due to two main characteristics: Accuracy & Variants. As quicker tests commonly referred to as Lateral Flow Tests become more popular, these will allow us to return to some sort of normality - mass testing. However these tests have faced a considerable backlash over accuracy and concerns around efficacy against specific variants. In settings where variant screening and accuracy are of paramount importance, PCR will continue to dominate. This includes hospitals, travel and care homes to name but a few.Market TrendsNovacyt has placed a big bet on rapid PCR testing outside of the lab. Through the introduction of VersaLab, PROMate, Q-Machines, Rapid HT-PCR tests and VariPlex, Novacyt has produced a service that enables people to conduct a PCR test outside of a lab with results available in 60-90 minutes. This is quite simply an unrivalled user experience and means the company is well positioned to capitalise on a decentralised diagnostics market going forward. It is also important to remember that Novacyt have over 550 tests allowing individuals to test for far more than just COVID-19.Unfortunately I think the COVID-19 pandemic is very similar to the way the market views technology trends. People over estimate the initial power of technology and significantly underestimate the power in the long term. In my opinion this can be applied to the pandemic: People overestimate how quickly it will subside and underestimate the longevity. Unfortunately as a result, testing could be here to stay for a significant period of time especially as variants continue to mutate as the virus comes under increasing pressure.FinancialsBased on 2020 figures and not taking into account the current DHSC dispute, Novacyt produced £277 million in revenue and £187 million EBITDA (margin of c.68%). EBITDA is then converted into cash at an 80% rate.Using this ratio, revenue of £72 million in Q1 2021 gives an EBITDA of c.£48 million resulting in cash of c.£38 million. This would put Novacyt's cash position at an eye watering £130 million.With the current market cap of £330 million, Novacyt would be valued at c.X2.5 cash position which seems incredibly cheap given the recent hiring spree, world class R&D, continued revenue production and consistent demand for their services. Sentiment is at an all time low with this stock however peers in the industry continue to be valued on X10 revenue as seen by recent M&A activity.There are definite headwinds for the company to deal with and their PR strategy has resulted in a number of disgruntled shareholders, however very few companies in the world have a gold standard product, operate at 80% margins, are completely debt free and sit on c.£100 million cash.
11/4/2021
11:07
nxc: Friday was painful but I think DHSC may well have done us a favour in the long term although it did not seem like that on Friday. Why. ? Because it forces Management to live with the reality of a post-Covid world earlier than others and I believe makes their paper more tradeable given the more diversified customer base and the installed instrument base. Key to the future will be the next acquisition(s) which should underpin the current share price and provide a basis for future share price growth. Novacyt are in a great position to acquire some mid-tier Diagnostic companies or be the lead vehicle in a SPAC. Last week saw Lumina be the lead in a SPAC valued at $5bn on a turnover of $140m ( albeit growing). Having a US listing would be hugely beneficial from a viewpoint of making acquisitions. It would be good to get some clarification regarding direction of travel - will they dive deeper into the molecular space e.g. Invitae,Saga Diagnostics, Clinspx Diagnostics, Hibergene or dive further into Point of Care with for example E77 or the old Orion Diagnostics subsidiary - there are plenty of fish in the sea - finding the right one is the challenge. Further clarity around the DHSC situation is required urgently but I suspect they cannot say much more at this point and we just need to be patient. A key part of the RNS relates to the continued take up at NHS level - this bodes well for the future long term prospects of Novacyt. Despite the set back Graham and the Board deserve to be supported - it is not their fault that DHSC have changed the rules of engagement once the game has started ( as evidenced by the reference to Q4). The DHSC not for the first time in this pandemic will be found wanting and an implicit warning to others resting on their goodwill.
11/4/2021
09:05
hatfullofsky: All credit to Rovers over on Stocko : Novacyt Sa (LON:NCYT): The Novacyt Share Price is an interesting one and as Paul mentioned above, a tough one to value. The NHS contract provided a steady stream of income however the price paid by the NHS was much lower than any private market ask. The UK Government is keen to move testing away from a centralised NHS offering to a private market as outlined in this recently released publication - Private COVID-19 testing validation - GOV.UK (www.gov.uk). PCR vs LFT PCR testing is here to stay due to two main characteristics: Accuracy & Variants. As quicker tests commonly referred to as Lateral Flow Tests become more popular, these will allow us to return to some sort of normality - mass testing. However these tests have faced a considerable backlash over accuracy and concerns around efficacy against specific variants. In settings where variant screening and accuracy are of paramount importance, PCR will continue to dominate. This includes hospitals, travel and care homes to name but a few. Market Trends Novacyt has placed a big bet on rapid PCR testing outside of the lab. Through the introduction of VersaLab, PROMate, Q-Machines, Rapid HT-PCR tests and VariPlex, Novacyt has produced a service that enables people to conduct a PCR test outside of a lab with results available in 60-90 minutes. This is quite simply an unrivalled user experience and means the company is well positioned to capitalise on a decentralised diagnostics market going forward. It is also important to remember that Novacyt have over 550 tests allowing individuals to test for far more than just COVID-19. Unfortunately I think the COVID-19 pandemic is very similar to the way the market views technology trends. People over estimate the initial power of technology and significantly underestimate the power in the long term. In my opinion this can be applied to the pandemic: People overestimate how quickly it will subside and underestimate the longevity. Unfortunately as a result, testing could be here to stay for a significant period of time especially as variants continue to mutate as the virus comes under increasing pressure. Financials Based on 2020 figures and not taking into account the current DHSC dispute, Novacyt produced £277 million in revenue and £187 million EBITDA (margin of c.68%). EBITDA is then converted into cash at an 80% rate. Using this ratio, revenue of £72 million in Q1 2021 gives an EBITDA of c.£48 million resulting in cash of c.£38 million. This would put Novacyt's cash position at an eye watering £130 million. With the current market cap of £330 million, Novacyt would be valued at c.X2.5 cash position which seems incredibly cheap given the recent hiring spree, world class R&D, continued revenue production and consistent demand for their services. Sentiment is at an all time low with this stock however peers in the industry continue to be valued on X10 revenue as seen by recent M&A activity. There are definite headwinds for the company to deal with and their PR strategy has resulted in a number of disgruntled shareholders, however very few companies in the world have a gold standard product, operate at 80% margins, are completely debt free and sit on c.£100 million cash.
10/4/2021
18:14
routy: Balanced post RBM Invest LSEHaving had a chance to sleep on yesterday's events, I can see this going one of just a few ways. NCYT cannot afford to be seen as an injured victim, nor will it's bigger investors. Although we'll be under initial attack on Monday, I wouldn't be surprised to see some big buys coming in. This could include NCYT itself, utilising some of it's huge cash balance to take a chunk of shares into treasury in order to steady the boat. A far better use of cash than letting it languish on account. In addition, the fundamentals are still strong at this share price value, so we could se the start of a TO becoming clear very quickly. This could prove the quickest route back to c.£10 share price levels, but a bargain if one of the big pharmas are on the look out for a proven testing innovator.Worryingly, when a company goes public stating that it's gone legal, it usually means that there has been a fundamental relationship breakdown. On that basis, any future additional HMG contracts have to now be viewed as a potential bonus. Losing this is massive, let's not be delusional and pretend otherwise, but there are many more huge markets that we appear to already be making good progress with. These have to be targeted aggressively and I really thing GM needs to make effort to give the markets a far better understanding of the current sales breakdown by market and by product. If they head down this route, we could see the share price consolidating and even a conservative rise. My only fear is that GM remains obstinate and believe that no action is required. Action is required and it revolves around, IMO, clear communication as to where we are now, where we want to get to and how we get there.We have come up against an unexpected hurdle, but not an insurmountable one. GM needs to stand up and lead the business out of this. Be innovative, be proactive and lead.I remain heavily invested and I remain positive, but we need to see some genuine leadership here. Otherwise, it will be a TO at the buyers terms....DYOR and good luck to all, no matter your decision.
10/4/2021
13:56
ihavelosteverything: HI FREEDOSH, I am 100% sure the share price will go back firmly to a much higher value, I am super tempted btw. Your 2K at the end of Friday's trading day is guaranteed to give you a profit. I am surprised nobody has mentioned the fact that the CEO G.M. has HALF A MILLION QUID bought at 800p AND the CFO (not a care taker or a poor technician ffs, but the chief financial officer) has 90k at 900p!!!! Do you think they will give up easily that huge amount of cash they are losing on paper? Their own company OF WHICH THEY HAVE FULL CONTROL!!!!?? The reason I wanted to transfer ALL my cash in NCYT a few days ago (but then jumped on the super hyped stock of the moment) was the INCREDIBLE number of staff constantly being hired. Would a NON growing (let alone struggling one) business hire so many new staff in such a short period of time ? Of course not! This company is hiring dozens of new employees and growing exponentially day by day, the sell off was utterly stupid. I hope to be able to buy at least 5k on Monday am but I doubt I will pay less than 5quid, even if I am quick at 8:01. PS Yes, I should use more than one basket and stop jumping, thanks for the reminder, I even missed like an idiot the amazing MHC Boots deal, 25% up intraday, sold the day before. Back anyway at a higher price and in profit.
09/4/2021
19:25
t_baggins: csmwssk12hu- On the 18th January you bought in and posted "covid is going nowhere". Then, you posted "740P was the base" and also posted at the same time... "back to £12?" Now that the UK has the lowest deaths in Europe, infections are falling like the ncyt share price, 740p was not the base and it never went back to £12, do you think maybe you should stop playacting the expect here ? LOL
07/4/2021
08:34
bobdown2: I think the managements carefull approach to forward looking figures and the gap between any such news has created an undeserved fear factor. If there is a big spike in the share price then maybe this side of managing the company should be looked at. The companies brokers guidance is double this share price.
07/4/2021
08:10
undervaluedassets: In terms of share price performance, we have to admit we have underperformed the other COVID testing stocks since the beginning of the year. However, In terms of business performance, we have outperformed the other UK COVID stocks since the beginning of the year. (evidence for which is that the workforce has more than doubled at NCYT as they are that busy) There is a building tension in the disparity between share price performance and business performance that is like an elastic band. This stretch one suspect will suddenly snap back and put NCYT on a rating that is more commensurate with its outperformance at a business level.
Novacyt share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
NCYT
Novacyt
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210415 12:42:48